An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis

International Journal of Hematology

Volumn 87, Issue 1, 2008, Pages 69-74

  Morita Hoshi, Yuriko ^a   Tohda, Shuji ^a   Miura, Osamu ^a   Nara, Nobuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

AA amyloidosis; Interstitial nephritis; Multicentric Castleman's Disease (MCD)

Indexed keywords

AMYLOID A PROTEIN; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; METHYLPREDNISOLONE; STEROID;

AA AMYLOIDOSIS; ADULT; AMYLOIDOSIS; ANAMNESIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AUTOPSY; BRAIN HEMORRHAGE; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HUMAN; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LABORATORY TEST; MALE; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PLASMA CELL; SKIN BIOPSY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AMYLOIDOSIS; FATAL OUTCOME; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL; SERUM AMYLOID A PROTEIN;

EID: 41849141226     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-007-0015-x     Document Type: Article

References (39)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer. 1956;9:822-30.
2. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276-80.
3. Tohda S, Murakami N, Nara N. Human herpesvirus 8 DNA in HIV-negative Japanese patients with multicentric Castleman's disease and related diseases. Int J Mol Med. 2001;8:549-51.
4. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670-83.
5. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202-16.
6. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol. 1993;20:636-47.
7. Bonneau R, Paquin F, Giroux L. Angiofollicular lymph node hyperplasia of the plasma cell type with nephrotic syndrome and systemic amyloidosis: an unusual association. Lab Invest. 1982;46:10-1.
8. Perfetti V, Bellotti V, Maggi A, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol. 1994;46:189-93.
9. Montoli A, Minola E, Stabile F, et al. End-stage renal failure from renal amyloidosis of the AA type associated with giant lymph node hyperplasia (Castleman's disease). Am J Nephrol. 1995;15:142-6.
10. Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995;122:395-6.
11. Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease. Nephron. 1995;71:463-4.
12. Arinsoy T, Yilmaz M, Ataoglu O, Bali M, Sindel S. Castleman's disease with renal amyloidosis and nephrotic syndrome. Nephrol Dial Transplant. 1997;12:2713-6.
13. Keven K, Nergizoglu G, Ates K, et al. Remission of nephrotic syndrome after removal of localized Castleman's disease. Am J Kidney Dis. 2000;35:1207-11.
14. Curioni S, D'Amico M, Quartagno R, Martino S, Dell'Antonio G, Cusi D. Castleman's disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16:1475-8.
15. Derici U, Arinsoy T, Ataoglu O, et al. Localized Castleman's disease and nephrotic syndrome not responsive to resection plus colchicine therapy. Ann Hematol. 2002;81:399-401.
16. Mandreoli M, Casanova S, Vianelli N, Pasquali S, Zucchelli P. Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman's disease. Nephron. 2002;90:336-40.
17. Leung KT, Wong KM, Choi KS, Chau KF, Li CS. Multicentric Castleman's disease complicated by secondary renal amyloidosis. Nephrology (Carlton). 2004;9:392-3.
18. Chan KW, Lo WK, Cheng IK. Nephrotic syndrome associated with angiofollicular lymph node hyperplasia, and subsequent amyloidosis. Pathology. 1992;24:229-30.
19. Tanaka K, Horita M, Shibayama H, et al. Secondary amyloidosis associated with Castleman's disease. Intern Med. 1995;34:122-26.
20. Lui SL, Chan KW, Li FK, Cheng IK, Chan TM. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron. 1998;78:323-7.
21. Diebold J, Tulliez M, Bernadou A, et al. Angiofollicular and plasmacytic polyadenopathy: a pseudotumourous syndrome with dysimmunity. J Clin Pathol. 1980;33:1068-76.
22. Frokjaer Thomsen O, Ladefoged J. Castleman's disease with renal infiltration by polyclonal plasma cells. Clin Nephrol. 1998;49:328-30.
23. Sato T, Wakabayashi Y, Hirasawa A, Tashiro Y, Nishikawa T, Chiba S. Multicentric Castleman's disease accompanied with both lymphoid interstitial pneumonia and interstitial nephritis. Rinsho Ketsueki. 1994;35:1322-8.
24. Summerfield GP, Taylor W, Bellingham AJ, Goldsmith HJ. Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin Pathol. 1983;36:1005-11.
25. Wu Q, Jinde K, Yanagi H, Endoh M, Sakai H. Acute interstitial nephritis with polyclonal B cell infiltration and development of mantle cell lymphoma. Intern Med. 2002;41:1158-62.
26. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360-7.
27. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56-61.
28. Garcia-SanMiguel J, Rozman C, Palacin A, Nomdedeu B. Mesenteric hyaline plasma cell lymph node hyperplasia sith amyloid deposits. Arch Intern Med. 1981;141:261-3.
29. Miura A, Sato I, Suzuki C. Fatal diarrhea in a patient with Castleman's disease associated with intestinal amyloidosis. Intern Med. 1995;34:1106-9.
30. Altiparmak MR, Pamuk GE, Pamuk ON, Dogusoy G. Secondary amyloidosis in Castleman's disease: review of the literature and report of a case. Ann Hematol. 2002;81:336-9.
31. Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM. 2002;95:211-8.
32. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82:766-8.
33. Yamagata N, Fujio J, Hirai R, et al. Marked hepatomegaly due to AA type amyloidosis in a case with Castleman's disease. Int J Hematol. 2006;84:70-3.
34. Androulaki A, Giaslakiotis K, Giakoumi X, Aessopos A, Lazaris AC. Localized Castleman's disease associated with systemic AA amyloidosis. Regression of amyloid deposits after tumor removal. Ann Hematol. 2007;86:55-7.
35. West KP, Morgan DR, Lauder I. Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J. 1989;65:108-11.
36. Pilon VA, Gomez LG, Butler JJ. Systemic amyloidosis associated with a benign mesenteric lymphoid mass. Am J Clin Pathol. 1982;78:112-6.
37. Carrington PA, Anderson H, Harris M, Walsh SE, Houghton JB, Morgenstern GR. Autoimmune cytopenias in Castleman's disease. Am J Clin Pathol. 1990;94:101-4.
38. Quinn JP, Gilligan OM, Horgan M. Evan's syndrome complicating multicentric Castleman's disease - dramatic response to rituximab. Eur J Haematol. 2004;73:384-5.
39. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96:2069-73.